Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All children up to 21 years of age, with central catheters (any type) that develop symptoms and are admitted to CHM with an underlying H/O/BMT diagnosis for individual episodes of suspected or proven CRI of the blood, including rule out sepsis, will be screened for potential participation in this study.~* Individual CRI episodes in the same patient will be defined as a distinct central catheter associated blood stream infection if separated by greater than 28 days from prior ELT procedure and caused by a different organism identified on culture than the prior central catheter associated blood stream infection episode.~* Participants meeting study enrollment criteria will be offered participation and must have parental full informed consent, adolescent assent and young child verbal assent prior to enrollment as applicable.~Exclusion Criteria:~* Children with documented allergy to ethanol or alcohol will be excluded. Blood cultures from patients that are reported positive for pathogen growth within 12 hours from the time they are obtained will be excluded from the study.~* Any patient at CHM with an infected central catheter and with another indwelling foreign body that communicates directly with the bloodstream, of which infection or colonization could not be excluded directly, will also be excluded from the study (i.e. Left Ventricular Assist Device) as it will not be possible to assess sterilization of the central catheter.~* Any patient with endocarditis or presumed endovascular infection will also be excluded.~* Any patient deemed critically ill or unstable, upon admission or during the early treatment course, in which case the treating clinician(s) feel that immediate line removal is potentially life-saving will be excluded from the study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Pre-emptive Ethanol Lock Therapy Group (Type: EXPERIMENTAL): Participants receive ethanol lock before blood cultures grow germ
- Standard Ethanol Lock Therapy Group (Type: ACTIVE_COMPARATOR): Participants receive ethanol lock if and only after blood cultures grow germ

Based on this trial design, predict the completion outcome and termination type (if applicable).